Merrill Goozner. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Angiogenesis Inhibitors/adverse effectsAngiogenesis Inhibitors/economicsAngiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedBevacizumabBreast Neoplasms/drug therapyBreast Neoplasms/pathologyClinical Trials as Topic/methodsDisease-Free SurvivalDrug Approval/methodsDrug IndustryFemaleHumansInsurance CoverageSurvival AnalysisTime FactorsTreatment OutcomeUncertaintyUnited StatesUnited States Food and Drug Administration
Substances: See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumab
Year: 2011 PMID: 21768534 DOI: 10.1093/jnci/djr293
Source DB: PubMed Journal: J Natl Cancer Inst ISSN: 0027-8874 Impact factor: 13.506